These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34476509)

  • 1. Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition.
    Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Pan J; Tungjai M
    Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34476509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pre-low-dose irradiation on anticancer activities of gallic acid in leukemic K562 and K562/Dox cells: cell viability and cellular energetic state studies.
    Aye KT; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
    Med Oncol; 2022 Sep; 39(12):229. PubMed ID: 36175689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of p-glycoprotein-mediated efflux pirarubicin in living multidrug-resistant K562/Dox cell lines by 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid via impairment of the cellular energetic state.
    Myint O; Wattanapongpitak S; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
    Toxicol Rep; 2022; 9():1443-1451. PubMed ID: 36518452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
    Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
    J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
    Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
    Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
    [No Abstract]   [Full Text] [Related]  

  • 6. The Effects of Iodinated Radiographic Contrast Media on Multidrug-resistant K562/Dox Cells: Mitochondria Impairment and P-glycoprotein Inhibition.
    Supawat B; Udomtanakunchai C; Kothan S; Tungjai M
    Cell Biochem Biophys; 2019 Jun; 77(2):157-163. PubMed ID: 30924055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
    Chen Y; Zhao Y; Wang C; Xiao X; Zhou X; Xu G
    Med Sci Monit; 2012 Oct; 18(10):BR383-8. PubMed ID: 23018344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
    Zhong J; Zhang J; Yu X; Zhang X; Dian L
    Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
    Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
    Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
    Wang HW; Ma KL; Liu H; Zhou JY
    Aging (Albany NY); 2020 Apr; 12(7):6018-6029. PubMed ID: 32259795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
    Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
    Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
    Chandramohan Reddy T; Bharat Reddy D; Aparna A; Arunasree KM; Gupta G; Achari C; Reddy GV; Lakshmipathi V; Subramanyam A; Reddanna P
    Toxicol In Vitro; 2012 Apr; 26(3):396-405. PubMed ID: 22245431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levistolide A synergistically enhances doxorubicin‑induced apoptosis of k562/dox cells by decreasing MDR1 expression through the ubiquitin pathway.
    Ding Y; Niu W; Zhang T; Wang J; Cao J; Chen H; Wang R; An H
    Oncol Rep; 2019 Feb; 41(2):1198-1208. PubMed ID: 30483812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
    Davies GF; Roesler WJ; Juurlink BH; Harkness TA
    Leuk Lymphoma; 2005 Aug; 46(8):1199-206. PubMed ID: 16085563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumvention of acquired resistance to doxorubicin in K562 human leukemia cells by oxatomide.
    Ishikawa M; Fujita R; Furusawa S; Takayanagi M; Sasaki K; Satoh S
    Biol Pharm Bull; 2001 Oct; 24(10):1185-7. PubMed ID: 11642329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
    Szwed M; Kania KD; Jozwiak Z
    Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
    Kostrzewa-Nowak D; Tarasiuk J
    Anticancer Res; 2021 Mar; 41(3):1429-1438. PubMed ID: 33788734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.